drugset / Trial / NCT00324077

Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase

NCT00324077

Phase 1 Withdrawn Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out whether adding a new drug, dasatinib, to imatinib is safe, and whether the combination of the two drugs will help decrease the number of cells that contain the Philadelphia chromosome.

Timeline

Start
2006-08
Primary completion
2007-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject dasatinib anhydrous Small molecule
Background Imatinib Small molecule